Mostrar el registro sencillo del ítem
Survival at 3, 6 and 12 months in patients diagnosed with Community-Acquired Pneumonia in Colombia
dc.contributor.author | Bastidas Goyes, Alirio | |
dc.contributor.author | Torres Arevalo, Daniela | |
dc.date.accessioned | 2023-09-04T16:12:30Z | |
dc.date.available | 2023-09-04T16:12:30Z | |
dc.date.issued | 2023-08-08 | |
dc.identifier.uri | http://hdl.handle.net/10818/56712 | |
dc.description | 29 páginas | es_CO |
dc.description.abstract | Background: In Colombia, there are no records showing long-term survival data for Community Acquired Pneumonia (CAP). Therefore, survival and risk factors in patients with this condition who required hospitalization are described. Methods: A retrospective cohort study was conducted in a high-complexity care center in Colombia, evaluating survival at 3, 6, and 12 months in CAP patients, using the Kaplan Meier method. Stratifications were made by age, sex, comorbidity, and severity. The comparison of survival curves was performed using the Log-Rank test, a multivariate analysis with Cox regression was performed to study possible risk factors that affected 12- month survival in patients with CAP. Results: 3688 subjects were admitted, with a mortality of 16.3% per year. Survival at three, six, and twelve months was 93.1%, 88.9%, and 84.5%, respectively. Analysis stratified by pneumonia severity index (PSI), 12-month survival was 98.7% in class-I, 95.6% in class-II, 87.41% in class-III, 77.1% in class IV, and 65.8% in class-V (p<0.001). Cox-regression showed that being male (HR: 1.44; 95% CI: 1.22-1.70; 0<0.001), an elevated PSI (HR: 4.22; 95%CI: 1.89-9.43; p<0.001), a high comorbidity index (HR: 2.29; 95%CI: 1.89-2.84; p<0.001) and vasopressor requirement (HR: 2.22; 95%CI <0.001) were associated with a lower survival at twelve months of follow-up. | en |
dc.format | application/pdf | es_CO |
dc.language.iso | eng | es_CO |
dc.publisher | Universidad de La Sabana | es_CO |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Universidad de La Sabana | |
dc.source | Intellectum Repositorio Universidad de La Sabana | |
dc.subject.other | Survival | |
dc.title | Survival at 3, 6 and 12 months in patients diagnosed with Community-Acquired Pneumonia in Colombia | en |
dc.title.alternative | Survival in patients diagnosed with CAP in Colombia | es_CO |
dc.type | master thesis | es_CO |
dc.type.hasVersion | publishedVersion | es_CO |
dc.rights.accessRights | restrictedAccess | es_CO |
dc.subject.armarc | Pneumonia | |
dc.subject.armarc | Risk factor | |
dcterms.references | Ferreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020;37(4):1302–18. | |
dcterms.references | Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346. | |
dcterms.references | Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, Bos LD, Chalmers JD, Derde L, de Waele J, Garnacho-Montero J, Kollef M, Luna CM, | |
dcterms.references | Menendez R, Niederman MS, Ponomarev D, Restrepo MI, Rigau D, Schultz MJ, Weiss E, Welte T, Wunderink R. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-632. | |
dcterms.references | Losier A, Dela Cruz CS. New testing guidelines for community-acquired pneumonia. Curr Opin Infect Dis. 2022 ;35(2):128-132. | |
dcterms.references | Kang SH, Jo YH, Lee JH, Jang DH, Kim YJ, Park I. Antibiotic prescription consistent with guidelines in emergency department is associated with 30-day survival in severe community-acquired pneumonia. BMC Emerg Med. 2021;21(1):1–9. | |
dcterms.references | Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J; CAPO Study Group. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest. 2010 ;138(2):279-83. | |
dcterms.references | Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 ;10(2):83-92 | |
dcterms.references | Saldías Peñafiel F, Román O F, Maturana O R, Díaz P O. Predictors of one year mortality among immunocompetent adults hospitalized for community-acquired pneumonia. Rev Med Chil. 2013;141(2):143–52. | |
dcterms.references | Schoenfeld DA. Sample-Size Formula for the Proportional-Hazards Regression Model. Biometrics. 1983 Jun;39(2):499. | |
dcterms.references | Mandell LA. Community-acquired pneumonia: An overview. Postgrad Med. 2015;127(6):607–15 | |
dcterms.references | Rider AC, Frazee BW. Community-Acquired Pneumonia. Emerg Med Clin North Am. 2018 ;36(4):665-683. | |
dcterms.references | ohnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: A populationbased cohort study. Medicine (Baltimore). 2008;87(6):329–34 | |
dcterms.references | Martínez-Vernaza S, Mckinley E, Soto MJ, Gualtero S. Neumonía adquirida en la comunidad : una revisión narrativa. 2018;(4). | |
dcterms.references | Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax. 2013;68(11):1057–65. | |
dcterms.references | Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83 | |
dcterms.references | Tokgoz Akyil F, Yalcinsoy M, Hazar A, Cilli A, Celenk B, Kilic O, et al. Prognosis of hospitalized patients with community-acquired pneumonia. Pulmonology. 2018 ;24(3):164–9. | |
dcterms.references | Renaud B, Coma E, Hayon J, Gurgui M, Longo C, Blancher M, Jouannic I, Betoulle S, Roupie E, Fine MJ; PNEUMOCOM study investigators. Investigation of the ability of the Pneumonia Severity Index to accurately predict clinically relevant outcomes: a European study. Clin Microbiol Infect. 2007 ;13(9):923-31. | |
dcterms.references | Cecere LM, Rubenfeld GD, Goss CH. Long-Term Survival after Hospitalization for Community-Acquired and Healthcare-Associated Pneumonia. 2010;98101:128–36. | |
dcterms.references | Ruiz LA, Serrano L, España PP, Martinez-Indart L, Gómez A, Uranga A, Castro S, Artaraz A, Zalacain R. Factors influencing long-term survival after hospitalization with pneumococcal pneumonia. J Infect. 2019 ;79(6):542-549. | |
dcterms.references | Welte T, Torres A, Nathwani D. Clinical and economic burden of communityacquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9. | |
dcterms.references | Yoshimoto A, Nakamura H, Fujimura M, Nakao S. Severe community-acquired pneumonia in an intensive care unit: Risk factors for mortality. Intern Med. 2005;44(7):710–6. | |
dcterms.references | Dupuis C, Sabra A, Patrier J, Chaize G, Saighi A, Féger C, Vainchtock A, Gaillat J, Timsit JF. Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs. Crit Care. 2021 ;25(1):24. | |
thesis.degree.discipline | Facultad de Medicina | es_CO |
thesis.degree.level | Maestría en Epidemiología | es_CO |
thesis.degree.name | Magíster en Epidemiología | es_CO |